<DOC>
	<DOCNO>NCT00008411</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop tumor cell divide stop grow die . PURPOSE : Randomized phase III trial determine effectiveness docetaxel treat patient metastatic breast cancer .</brief_summary>
	<brief_title>Docetaxel Treating Patients With Metastatic Breast Cancer</brief_title>
	<detailed_description>OBJECTIVES : - Compare objective tumor response rate , duration response , time progression , progression-free survival , overall survival woman metastatic breast cancer treat docetaxel administer weekly v every three week . - Compare safety toxicity regimens patient . - Evaluate maintenance relative dose intensity regimen patient . - Correlate pretreatment serum HER2/neu level response docetaxel therapy patient . OUTLINE : This randomize , multicenter study . Patients stratify accord prior taxane use ( yes v ) , number prior chemotherapy regimens metastatic disease ( 0 vs 1 ) , participate center . Patients randomize one two treatment arm . - Arm I : Patients receive docetaxel IV 1 hour day 1 . Courses repeat every 21 day . - Arm II : Patients receive docetaxel IV 30 minute day 1 , 8 , 15 . Courses repeat every 28 day . Treatment continue arm absence disease progression unacceptable toxicity . Patients follow 3 week , 3 , 6 , 9 , 12 month , annually 4 year . PROJECTED ACCRUAL : A total 160 patient accrue study .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm metastatic breast cancer Bidimensionally measurable disease No uncontrolled brain metastasis leptomeningeal disease Hormone receptor status : Not specify PATIENT CHARACTERISTICS : Age : 18 Sex : Female Menopausal status : Not specify Performance status : Zubrod 02 Life expectancy : At least 3 month Hematopoietic : Platelet count least 100,000/mm^3 Neutrophil count least 1,000/mm^3 Hemoglobin least 8 g/dL Hepatic : Bilirubin great upper limit normal ( ULN ) SGOT/SGPT great 1.5 time ULN ( 2.5 time ULN provide alkaline phosphatase great ULN ) Alkaline phosphatase great 2.5 time ULN ( 4 time ULN provide transaminase great ULN ) Renal : Creatinine great 2.0 mg/dL Neurologic : No peripheral neuropathy grade 2 great Neurologic status must stable 2 week surgery and/or radiotherapy brain metastasis No psychiatric disorder Other : Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception No malignancy within past 5 year except nonmelanoma skin cancer , carcinoma situ cervix , curatively treated malignancy No serious condition illness , include active infection No history hypersensitivity polysorbate 80 PRIOR CONCURRENT THERAPY : Biologic therapy : Not specify Chemotherapy : Recovered prior chemotherapy No 2 prior chemotherapy regimen ( 1 prior regimen metastatic disease ) No prior paclitaxel docetaxel ( except adjuvant setting ) At least 12 month since prior adjuvant taxane ( paclitaxel docetaxel ) Prior anthracyclinebased therapy allow Endocrine therapy : Not specify Radiotherapy : At least 2 week since prior radiotherapy recover Surgery : At least 2 week since prior surgery recover</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2012</verification_date>
	<keyword>stage IV breast cancer</keyword>
	<keyword>recurrent breast cancer</keyword>
</DOC>